Stay updated with breaking news from Clinical. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
.png?height=418&t=1670008838&width=800)
Top-line data from Glycomimetics Inc.’s pivotal phase III study of uproleselan in 388 patients with relapsed/refractory acute myeloid leukemia missed its primary endpoint. The data crippled the stock, which closed at the low point of its 10-year existence.
Less than a week ago, executives at Lyra Therapeutics Inc. were looking ahead to “imminent” data from its first phase III study in chronic rhinosinusitis (CRS), testing drug-device candidate LYR-210, a drug-device candidate largely expected to fill a much-needed gap in CRS treatment. On Monday, May 6, they were announcing plans to preserve cash in the wake of the failed Enlighten 1 study, which raised doubts as to the feasibility of the company’s CRS programs, which also include the similarly designed candidate LYR-220.
Clinical psychologist Glenda Graham suffered delays in treatment for her endometrial cancer before her death in October 2020. Health NZ is now investigating...
The University of Arkansas Pulaski Technical College Foundation is set to receive a $93,500 grant from The Windgate Foundation.The college will use this grant t
DOHA: Her Highness Sheikha Moza bint Nasser, Chairperson of Qatar Foundation, attended a panel discussion focusing on laying the foundations for personalized medicine in clinical...